Research Topics
| Jakko van IngenSummaryAffiliation: National Institute for Public Health and the Environment Country: The Netherlands Publications
| Collaborators
|
Detail Information
Publications
Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving anti-tumor necrosis factor therapyJakko van Ingen
Department of Pulmonary Diseases, Radboud University, Nijmegen Medical Centre, and the Rijnstate Hospital in Arnhem, The Netherlands
Nat Clin Pract Rheumatol 3:414-9. 2007..His medication at presentation consisted of etanercept, azathioprine, naproxen and inhaled fluticasone and salbutamol...
Re-analysis of 178 previously unidentifiable Mycobacterium isolates in the Netherlands in 1999-2007J van Ingen
Department of Pulmonary Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
Clin Microbiol Infect 16:1470-4. 2010..The number of NTM species in the environment is probably so high that unidentifiable clinical isolates should be given a separate species status only if this is clinically meaningful...- Isolation of mycobacteria other than Mycobacterium avium from porcine lymph nodesJakko van Ingen
National Mycobacteria Reference Laboratory, National Institute for Public Health and the Environment, Bilthoven, The Netherlands
Vet Microbiol 144:250-3. 2010..The species distribution shows interesting parallels with human NTM lymphadenitis. Molecular typing and environmental sampling studies are required to identify the sources of these infections... 
Comparative study on genotypic and phenotypic second-line drug resistance testing of Mycobacterium tuberculosis complex isolatesJakko van Ingen
National Institute for Public Health and the Environment, National Mycobacteria Reference Laboratory, Bilthoven, Netherlands
J Clin Microbiol 48:2749-53. 2010..The genotypic assay proved a reliable and rapid method for predicting aminoglycoside and fluoroquinolone resistance...- Rapidly growing nontuberculous mycobacteria cultured from home tap and shower waterJakko van Ingen
National Tuberculosis Reference Laboratory, National Institute for Public Health and the Environment RIVM, Bilthoven, The Netherlands
Appl Environ Microbiol 76:6017-9. 2010..Cultures yielded Mycobacterium peregrinum, M. salmoniphilum, M. llatzerense, M. septicum, and three potentially novel species, a distribution different from that in clinical samples... - Environmental sources of rapid growing nontuberculous mycobacteria causing disease in humansJ van Ingen
Department of Pulmonary Diseases, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
Clin Microbiol Infect 15:888-93. 2009..Furthermore, studies should focus on the actual sites of the active replication of RGM; their presence may not indicate their natural habitat... - Clinical relevance of Mycobacterium chelonae-abscessus group isolation in 95 patientsJakko van Ingen
Department of Pulmonary Diseases, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
J Infect 59:324-31. 2009..To determine the clinical relevance of Mycobacterium chelonae-abscessus group isolation from clinical samples... - Mycobacterium mantenii sp. nov., a pathogenic, slowly growing, scotochromogenic speciesJakko van Ingen
Department of Pulmonary Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
Int J Syst Evol Microbiol 59:2782-7. 2009..We propose the name Mycobacterium mantenii sp. nov. for this novel species. The type strain, isolated from a lymph node biopsy sample, is strain 04-1474(T) (=NLA000401474(T) =CIP 109863(T) =DSM 45255(T))... - Proposal to elevate Mycobacterium avium complex ITS sequevar MAC-Q to Mycobacterium vulneris sp. novJ van Ingen
Department of Pulmonary Diseases, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
Int J Syst Evol Microbiol 59:2277-82. 2009..avium complex strains sharing this 16S gene and MAC-Q ITS sequence to separate species status, for which the name Mycobacterium vulneris sp. nov. is proposed. The type strain is NLA000700772T (=DSM 45247T=CIP 109859T)... - Region of difference 1 in nontuberculous Mycobacterium species adds a phylogenetic and taxonomical characterJakko van Ingen
National Mycobacteria Reference Laboratory, Laboratories for Infectious Diseases and Perinatal Screening, National Institute for Public Health and the Environment, Bilthoven, The Netherlands
J Bacteriol 191:5865-7. 2009..kansasii, M. szulgai, M. marinum, and M. riyadhense, with unique sequences. This adds a phylogenetic and taxonomical characteristic and may represent a virulence factor for nontuberculous mycobacteria... - Mycobacterium riyadhense sp. nov., a non-tuberculous species identified as Mycobacterium tuberculosis complex by a commercial line-probe assayJakko van Ingen
National Mycobacteria Reference Laboratory, National Institute for Public Health and the Environment, Bilthoven, The Netherlands
Int J Syst Evol Microbiol 59:1049-53. 2009..We propose the name Mycobacterium riyadhense sp. nov. to accommodate this strain. The type strain is NLA000201958(T) (=CIP 109808(T) =DSM 45176(T))... - Mycobacterium noviomagense sp. nov.; clinical relevance evaluated in 17 patientsJakko van Ingen
Radboud University Nijmegen Medical Center, Department of Pulmonary Diseases, Nijmegen, The Netherlands
Int J Syst Evol Microbiol 59:845-9. 2009..nov. is proposed for the novel strains. The type strain is NLA000500338(T) (=DSM 45145(T)=CIP 109766(T)). A more distinctive taxonomy of NTM is a prerequisite for the assessment of their clinical relevance... - Clinical Mycobacterium conspicuum isolation from two immunocompetent patients in The NetherlandsJ van Ingen
Department of Pulmonary Diseases, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
J Clin Microbiol 45:4075-6. 2007 - Clinical relevance of Mycobacterium simiae in pulmonary samplesJ van Ingen
Dept of Pulmonary Diseases, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
Eur Respir J 31:106-9. 2008..simiae infection. Further studies are required in order to improve diagnostic criteria and treatment regimens... - The changing pattern of clinical Mycobacterium avium isolation in the NetherlandsJ van Ingen
Department of Pulmonary Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
Int J Tuberc Lung Dis 14:1176-80. 2010..National Mycobacteria Reference Laboratory, The Netherlands... - Second-line drug resistance in multidrug-resistant tuberculosis cases of various origins in the NetherlandsJ van Ingen
Department of Pulmonary Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
Int J Tuberc Lung Dis 12:1295-9. 2008..The Netherlands... - Mycobacterial disease in patients with rheumatic diseaseJakko van Ingen
Respiratory Diseases Department, Radboud University Nijmegen Medical Center, The Netherlands
Nat Clin Pract Rheumatol 4:649-56. 2008..Further studies are needed to determine the prevalence of NTM disease in this setting, and to evaluate the safety of simultaneous anti-TNF and antimycobacterial treatment... - Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The NetherlandsJ van Ingen
Department of Pulmonary Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
Thorax 64:502-6. 2009..The frequency of clinical isolation of non-tuberculous mycobacteria (NTM) in the Netherlands is increasing, but its clinical relevance is often uncertain... - [Nontuberculous mycobacteria: clinically relevant]Jakko van Ingen
Radboud Universiteit Nijmegen Medisch Centrum, afd Longziekten, Nijmegen, en Universitair Centrum voor Chronische Ziekten Dekkerswald, Groesbeek, The Netherlands
Ned Tijdschr Geneeskd 154:A1178. 2010..Therefore, prompt consultation with one of the specialized centres of expertise is warranted. We should also consider formulating national guidelines for diagnosis and treatment... - Mycobacterium sherrisii sp. nov., a slow-growing non-chromogenic speciesJakko van Ingen
Department of Pulmonary Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
Int J Syst Evol Microbiol 61:1293-8. 2011..5 % (391/401 bp) and 95.2 % (700/735 bp), respectively. On the basis of these results, we propose the formal recognition of Mycobacterium sherrisii sp. nov. The type strain is 4773(T) ( = ATCC BAA-832(T) = DSM 45441(T))... - Clinical relevance of Mycobacterium szulgai in The NetherlandsJakko van Ingen
Department of Pulmonary Diseases, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
Clin Infect Dis 46:1200-5. 2008..The clinical relevance of Mycobacterium szulgai isolates is unknown, and available literature focuses on case reports of M. szulgai disease. We assessed the clinical relevance of M. szulgai isolated from patients in The Netherlands... - Mycobacterium xenopi clinical relevance and determinants, the NetherlandsJakko van Ingen
Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
Emerg Infect Dis 14:385-9. 2008..Most infections were pulmonary, but pleural and spinal infections (spinal in HIV-infected patients) were also noted. Treatment regimens varied in content and duration; some patients were over-treated and some were undertreated... - In vitro drug susceptibility of 2275 clinical non-tuberculous Mycobacterium isolates of 49 species in The NetherlandsJakko van Ingen
Department of Pulmonary Diseases, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
Int J Antimicrob Agents 35:169-73. 2010..To improve the utility of drug susceptibility testing, the selection of drugs should be changed to more drugs with proven clinical efficacy correlating with in vitro susceptibility... - Low rate of fluoroquinolone resistance in Mycobacterium tuberculosis isolates from northern TanzaniaJossy van den Boogaard
Radboud University Nijmegen Medical Centre, University Centre for Chronic Diseases Dekkerswald, PO Box 66, 6560 AB, Groesbeek, The Netherlands
J Antimicrob Chemother 66:1810-4. 2011..We determined the rate of fluoroquinolone resistance in M. tuberculosis isolates obtained from Tanzanian patients and linked this to previous fluoroquinolone exposure and mycobacterial resistance to rifampicin and isoniazid... - Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamideSami O Simons
Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
J Clin Microbiol 50:428-34. 2012.... - Are phylogenetic position, virulence, drug susceptibility and in vivo response to treatment in mycobacteria interrelated?Jakko van Ingen
Department of Clinical Microbiology, Radboud University Nijmegen Medical Center, P O Box 9101, 6500 HB Nijmegen, The Netherlands
Infect Genet Evol 12:832-7. 2012.... - Characterization of Mycobacterium orygis as M. tuberculosis complex subspeciesJakko van Ingen
Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
Emerg Infect Dis 18:653-5. 2012..We characterized 22 isolates by molecular methods and propose elevation to subspecies status as M. orygis. M. orygis is a causative agent of tuberculosis in animals and humans from Africa and South Asia... - Nontuberculous mycobacteria in respiratory tract infections, eastern AsiaSami Simons
Department of Pulmonary Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
Emerg Infect Dis 17:343-9. 2011..This geographic variation is not well reflected in the American Thoracic Society criteria for NTM infections and could be incorporated in future guidelines... - The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatmentJakko van Ingen
Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, CO, USA
Am J Respir Crit Care Med 186:559-65. 2012..Currently recommended multidrug treatment regimens for Mycobacterium avium complex (MAC) lung disease yield limited cure rates. This results, in part, from incomplete understanding of the pharmacokinetics and pharmacodynamics of the drugs... - Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?Jakko van Ingen
University Center for Chronic Diseases Dekkerswald and Department of Pulmonary Diseases, Radboud University Nijmegen MedicalCenter, Nijmegen, The Netherlands
Clin Infect Dis 52:e194-9. 2011..The reduced cost and the lack of evidence of toxicity at higher daily doses remove the other arguments. To optimize tuberculosis treatment, the clinical value of higher doses of rifampicin should be tested in clinical trials... - Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteriaJakko van Ingen
Department of Clinical Microbiology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
Drug Resist Updat 15:149-61. 2012..This review provides a comprehensive overview of the mechanisms of drug resistance in NTM, phenotypic methods for testing susceptibility in past and current use for DST of NTM, as well as molecular approaches to assess drug resistance... - The broad-spectrum antimycobacterial activities of phenothiazines, InVitro: somewhere in all of this there may be patentable potentialsJakko van Ingen
Department of Clinical Microbiology 574, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
Recent Pat Antiinfect Drug Discov 6:104-9. 2011..New drugs for treatment of mycobacterial disease, most notable multidrug- and extensively drug-resistant tuberculosis, are urgently needed; phenothiazines and their targets should be exploited for this use... - Otomastoiditis Caused by Mycobacterium abscessus, the NetherlandsJakko van Ingen
Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands J van Ingen, F Looijmans, R Dekhuijzen, M Boeree National Institute for Public Health and the Environment, Bilthoven, the Netherlands J van Ingen, D van Soolingen and Academic Medical Centre, Amsterdam, the Netherlands P Mirck
Emerg Infect Dis 16:166-8. 2010.... - Comparative study of IS6110 restriction fragment length polymorphism and variable-number tandem-repeat typing of Mycobacterium tuberculosis isolates in the Netherlands, based on a 5-year nationwide surveyJessica L de Beer
National Tuberculosis Reference Laboratory, Laboratory for Infectious Diseases and Perinatal Screening LIS, Centre for Infectious Disease Control CIb, National Institute for Public Health and the Environment RIVM, Bilthoven, The Netherlands
J Clin Microbiol 51:1193-8. 2013..Both aspects make VNTR typing a suitable method for tuberculosis surveillance systems... - Drug susceptibility testing and pharmacokinetics question current treatment regimens in Mycobacterium simiae complex diseaseJakko van Ingen
Division of Mycobacterial and Respiratory Infections, National Jewish Health, 1400 Jackson Street, Denver, CO 80206, USA
Int J Antimicrob Agents 39:173-6. 2012..simiae disease. A treatment regimen including a macrolide, moxifloxacin and one or two additional drugs based on DST results may be advisable; clofazimine and amikacin or streptomycin are potential candidates...